Can Auvelity (dextromethorphan/bupropion) 45‑105 mg daily, Rexulti (brexpiprazole) 1 mg each morning, and Belsomra (suvorexant) 10 mg at bedtime be taken together, and what are the potential drug‑drug interactions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Drug Interaction Assessment: Auvelity, Rexulti, and Belsomra Combination

This three-drug combination carries significant CNS polypharmacy risk and should be used with heightened caution, particularly in older adults, but is not absolutely contraindicated if clinically necessary with close monitoring.

Critical Interaction Concerns

CNS Polypharmacy Warning

The most important consideration is that this regimen combines three CNS-active agents (an antidepressant, an antipsychotic, and a hypnotic), which the 2019 AGS Beers Criteria explicitly warns against 1. The guideline states that concurrent use of three or more CNS agents (including antidepressants, antipsychotics, and nonbenzodiazepine receptor agonist hypnotics like Belsomra) significantly increases fall risk and should be avoided in older adults.

Key risks with this combination:

  • Increased fall risk (particularly concerning with suvorexant's sedative effects)
  • Additive CNS depression (sedation, dizziness, cognitive impairment)
  • Psychomotor impairment

Specific Drug-Drug Interactions

Auvelity-Specific Considerations

Bupropion component interactions:

  • Bupropion is a CYP2D6 inhibitor (this is actually therapeutic in Auvelity, as it increases dextromethorphan levels) 2
  • The FDA label explicitly warns about alcohol intolerance and advises limiting alcohol use 2
  • Must screen for other bupropion-containing products to avoid duplication 2

Dextromethorphan component:

  • Must screen for other dextromethorphan-containing products (common in OTC cough medications) 2
  • The AGS Beers Criteria notes that dextromethorphan/quinidine combinations increase fall risk and drug-drug interaction potential 1

Brexpiprazole (Rexulti) Interactions

Brexpiprazole has minimal interaction potential with this regimen:

  • Shows weak inhibitory effects on CYP enzymes (IC50 >13 μmol/L for most) 3
  • No clinically significant transporter interactions at therapeutic doses 3
  • Not a significant CYP2D6 inhibitor or substrate, so no major pharmacokinetic interaction with Auvelity expected

Suvorexant (Belsomra) Considerations

  • Primarily metabolized by CYP3A4, not CYP2D6, so no direct pharmacokinetic interaction with Auvelity's bupropion component
  • Main concern is additive CNS depression when combined with other psychotropic medications
  • The 10 mg dose is already at bedtime (note: your prescription says "qAM" but this appears to be an error—Belsomra should be taken at bedtime)

Clinical Management Algorithm

1. Patient Risk Stratification

  • Age ≥65 years: High-risk population per Beers Criteria—consider alternative strategies
  • Fall history: Document baseline fall risk; if present, strongly reconsider this combination
  • Renal function: If eGFR 30-59 mL/min, Auvelity dose must be reduced to once daily 2

2. Monitoring Requirements

Before initiating:

  • Blood pressure assessment (Auvelity can increase BP) 2
  • Screen for bipolar disorder history 2
  • Verify no other bupropion or dextromethorphan products
  • Assess baseline fall risk and cognitive function

During treatment:

  • Monitor blood pressure periodically 2
  • Assess for excessive sedation, dizziness, or psychomotor impairment at each visit
  • Document any falls or near-falls
  • Monitor for suicidal ideation (particularly first 4 weeks) 2

3. Dosing Correction Needed

Your prescription states "Belsomra 10 mg po qAM"—this is incorrect. Suvorexant must be taken at bedtime, not in the morning. The timing should be:

  • Auvelity: Once daily in morning (or twice daily after day 3 if tolerated)
  • Rexulti: 1 mg in morning
  • Belsomra: 10 mg at bedtime (HS), NOT qAM

Common Pitfalls to Avoid

  1. Do not prescribe Belsomra in the morning—this will cause daytime sedation and significantly increase fall/accident risk
  2. Do not overlook OTC medications—patients may unknowingly take dextromethorphan-containing cough products
  3. Do not ignore alcohol use—Auvelity specifically warns about reduced alcohol tolerance 2
  4. Do not prescribe this combination in patients with seizure disorders—Auvelity is absolutely contraindicated 2
  5. In older adults, strongly consider whether all three agents are necessary—the Beers Criteria recommendation against 3+ CNS agents is strong 1

When This Combination May Be Justified

Despite the concerns, this combination may be appropriate when:

  • Patient has treatment-resistant depression requiring Auvelity
  • Psychotic features or severe agitation necessitate Rexulti augmentation
  • Significant insomnia impairs functioning and requires Belsomra
  • Patient is younger than 65 years with no fall history
  • Close monitoring is feasible

The benefit must clearly outweigh the CNS polypharmacy risks, and alternatives should be exhausted first.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.